Browsing by Author Australian Ovarian Cancer Study Group, (AOCSG)

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 4 of 4
Issue DateTitleAuthor(s)Citation
2011IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell CancerdeFazio, Anna; Anglesio, Michael S.; Australian Ovarian Cancer Study Group, (AOCSG); Balkwill, Frances; Birrer, Michael J.; Bowtell, David D L; Campbell, Ian G.; Chakravarty, Probir; Coward, Jermaine; Cowin, Prue; Friedlander, Michael L.; George, Joshy; Gilks, B; Gorringe, Kylie; House, Colin; Huntsman, David; Kalloger, Steve; Kulbe, Hagen; Lemech, Charlotte; Okamoto, Aikou; Power, Jeremy; Rischin, D.; Western Clinical School: Westmead Millennium InstituteIL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer, Clinical Cancer Research, vol.17, 8, 2011,pp 2538-2548
2010Medical costs and outcomes for Australian women with ovarian cancer: a patient-level analysis over 2.5 yearsdeFazio, Anna; Australian Ovarian Cancer Study Group, (AOCSG); Beesley, Vanessa; Clavarino, Alexandra; Gordon, Louisa; Green, Adele C.; Scuffham, Paul A; Webb, Penelope M.; Wyld, David; Western Clinical School: Westmead Millennium InstituteMedical costs and outcomes for Australian women with ovarian cancer: a patient-level analysis over 2.5 years, International Journal of Gynecological Cancer, vol.20, 5,pp 757-765
2008Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.deFazio, Anna; Russell, Peter; Anglesio, Michael S.; Arnold, Jeremy; Australian Ovarian Cancer Study Group, (AOCSG); Birrer, Michael J.; Bowtell, David D L; Chenevix-Trench, Georgia; Fereday, Sian; George, Joshy; Locandro, Bianca; Sharma, Raghwa; Simms, Lisa; Tinker, A. V.; Tothill, Richard W.; Traficante, Nadia; Waddell, Nic; Western Clinical School: Westmead Millennium Institute; Central Clinical School: PathologyMutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors., Molecular Cancer Research, vol.6, 11, 2008,pp 1678-1690
2008Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.deFazio, Anna; Australian Ovarian Cancer Study Group, (AOCSG); Bowtell, David D L; Brown, Robert; Chiew, Yoke-Eng; Etemadmoghadam, Dariush; Fereday, Sian; Fox, Stephen B.; George, Joshy; Gertig, Dorota; Haviv, Izhak; Hung, Jillian A.; Johnson,, Daryl S.; Lade, Stephen; Locandro, Bianca; Tinker, Anna V.; Tothill, Richard W.; Traficante, Nadia; Trivett, Melanie K.; Western Clinical School: Westmead Millennium InstituteNovel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome., Clinical Cancer Research, vol.14, 16, 2008,pp 5198-5208